




Global position paper 2026

Position on Pricing & Patient Access



Ditte,
living with schizophrenia

At Lundbeck we aspire to impact patients and society through leading innovation within neuroscience, while delivering sustainable growth as a Focused Innovator. Our purpose is to develop transformative therapies and ensure that eligible patients can access them. The Position on Pricing and Patient Access outlines how we support equitable global access, set prices responsibly, and contribute to sustainable healthcare systems.



Improve access for patients

The global healthcare environment is evolving, including the rising demand for healthcare systems to provide access to innovative medicines.

In this context, our role within Lundbeck is to enable access to our medicines and to ensure that stakeholders (i.e. payers and reimbursement authorities, clinicians, policymakers, and patients) recognize their full value.

As we continue advancing brain science and deliver transformative therapies, we recognize that our innovations have meaning only when people can afford

and access them. We have a responsibility to not just develop innovative treatments, but to also support patients access them. To ensure that, we are working with governments and healthcare systems to identify solutions that improve patient access to medicines, support sustainable healthcare systems, and enable reinvestment of revenues into future research and medical innovation.



Our approach to pricing and access



Pricing and affordability
Fair and sustainable pricing principles



Value-based pricing
Pricing reflects demonstrated value

We believe access is a shared responsibility between manufacturers, healthcare systems, governments, and payers.

We work collaboratively to expand reimbursement and availability of new medicines to eligible patients in markets where we operate. For that, we work proactively with payers, Health Technology Assessment (HTA) bodies, clinicians, and policymakers to ensure that the value of

our medicines is accurately acknowledged and reflected in reimbursement decisions. This engagement is essential to ensuring patients gain timely access to our innovations and that healthcare systems can support new treatments in a sustainable way.

We assess the value our medicines deliver on several factors, including:



Clinical outcomes

- the benefit our medicines have on patients.



Economic value

- through cost effectiveness and reduced healthcare burden.



Social benefit

- highlighting the medicines' impact on Quality of Life



Whilst enabling eligible patients access to our medicines, we commit to address affordability challenges where relevant, and to contribute to sustainable health-care systems through responsible pricing practices.

To promote fairness and affordability, we apply an Equity-Based Tiered Pricing framework based on macroeconomic indicators such as Gross Domestic Product (GDP) per capita, public health spending, and overall ability-to-pay. This framework reflects our commitment to responsible and equitable pricing.

To further guide our impact towards enhancing access to brain health, Lundbeck established two key Patient Access Metrics (PAMs) in 2025, to assess how efficiently our medicines secure patient access following market authorization. The two metrics, Access Coverage and Time to Access indicator enable Lundbeck to monitor our patient access performance, benchmark against industry standards and identify opportunities to close access gaps and establish long term goals.

Lundbeck considers equity based tiered pricing a key metric in its pricing and access governance across all brands. Lundbeck's framework defines equity considering Ability-To-Pay adjusted for income inequality. This framework is used to cluster countries based on the macro-economic environment to make informed decisions on fair pricing.

Lundbeck's Patient Access Metrics



Access coverage

Access coverage for eligible patients across countries where we operate. Higher Access Coverage % means more patients have access to our medicines under public reimbursement.



Time to Access Indicator

Efficient and timely access to our medicines. Higher Time to Access Indicator % means less wait for patients to access our medicines under public reimbursement.



Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric disorders.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and

neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

